the LSE, admission and listing of Shire
Limited ordinary shares, commencement of
dealings and crediting of Shire Limited
ordinary shares in uncertificated form to
Within 10 Despatch of share certificates in respect
Business Days of Shire Limited ordinary shares in
after the Scheme certificated form.
This timetable is based on the Board's expectations and may be subject to change. Any changes to the timetable will be the subject of a further announcement. Key dates relevant to the holders of Shire ADSs may differ from those above and will be set out in full in the Circular.
Morgan Stanley & Co. International plc is acting as sponsor to Shire Limited's listing and as joint corporate broker. Deutsche Bank AG London is acting as joint corporate broker.
Notes to editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com
This announcement does
|SOURCE Shire PLC|
Copyright©2008 PR Newswire.
All rights reserved